Alembic Pharma successfully completes USFDA inspection at Panelav Oncology formulation facility
Vadodara: Alembic Pharma has announced that the Company has successfully completed the United States Food and Drug Administration (USFDA) inspection for its Oncology (Injectable and Oral Solid) Formulation Facility (F-2) located at Panelav.
The inspection was successfully completed without any Form 483 observation.
The inspection was conducted from 7th October, 2024 to 8th October, 2024.
Medical Dialogues team had earlier reported that the Company had received an Establishment Inspection Report (EIR) from the USFDA for inspection carried out at the Company's Oral Solid Formulation Facility (F-I) at Panelav.
Alembic Pharmaceuticals Limited is a vertically integrated research and development pharmaceutical company. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA.
Next Story
